Pilot study to assess biochemical efficacy of 2 dialysis membranes in the setting of nocturnal haemodialysis.
Not Applicable
- Conditions
- Dialysis dependent end-stage renal failureRenal and Urogenital - Kidney disease
- Registration Number
- ACTRN12619000424101
- Lead Sponsor
- Monash Health, Clayton, Vic,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Existing nocturnal haemodialysis patients.
Exclusion Criteria
Those with dialysis difficulties, such as poor Arterio-venous access.
Those unwilling to consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of dialysis - as measured by removal of uremic toxins (eg. urea, creatinine, phosphate, indoxyl sulfate, beta-2 microglobulin, alpha-1 microglobulin).<br>This will be assessed as reduction ratios - utilising blood samples from before the session and immediately after the session, with the reduction ratio calculated as Pre-Post/Pre x 100 (as a unitless number).<br>In addition instantaneous clearances will be calculated 1 hour into dialysis with blood samples from pre and post the dialysis membrane (also called arterial and venous samples), with the calculation Art-Ven/Art x 100.<br>Finally, the actual amount of each toxin removed, as appearing in the spent dialysate, will be calculated using partial dialysate collections.[The primary outcome (clearance) will be assessed at a single time point - being the mid-week session of the 4th week.]
- Secondary Outcome Measures
Name Time Method Safety of each membrane, as determined by haematological markers (FBE, clotting)[4 weeks, for each membrane]